Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Long-Term Investments (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Long-Term Investments for 4 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Investments changed 0.2% to $2.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 million, a 0.2% change, with the full-year FY2024 number at $2.5 million, changed 0.2% from a year prior.
  • Long-Term Investments was $2.5 million for Q3 2025 at Orchestra BioMed Holdings, roughly flat from $2.5 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $160.2 million in Q2 2022 to a low of $2.5 million in Q4 2022.
  • A 4-year average of $18.4 million and a median of $2.5 million in 2022 define the central range for Long-Term Investments.
  • Peak YoY movement for Long-Term Investments: tumbled 98.44% in 2023, then rose 0.2% in 2024.
  • Orchestra BioMed Holdings' Long-Term Investments stood at $2.5 million in 2022, then changed by 0.0% to $2.5 million in 2023, then grew by 0.2% to $2.5 million in 2024, then changed by 0.0% to $2.5 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Long-Term Investments are $2.5 million (Q3 2025), $2.5 million (Q2 2025), and $2.5 million (Q1 2025).